MD Anderson at the 2020 AACR Virtual Annual Meeting II

June 22-24, 2020

THE UNIVERSITY OF TEXAS
MD Anderson Cancer Center
Making Cancer History®

STREAMING PRESENTATIONS			
Monday, June 22			
TIME	**SESSION**	**ABSTRACT**	**PRESENTER**
1:30-3:30 p.m. EDT (1:30-1:50 p.m.)	Virtual Educational Session – Evaluating Immunocompetent Models to Build Greater Success in Cancer Immunotherapy	*Session Chairperson - Immune checkpoint therapy: Evaluating human immune responses*	**Padmanee Sharma, M.D., Ph.D.**
Tuesday, June 23			
TIME	**SESSION**	**ABSTRACT**	**PRESENTER**
9:00-10:45 a.m. EDT (9:20-9:30 a.m.)	Virtual Minisymposium – Circulating Tumor DNA for Patient Stratification	*3385: Liquid biopsy to detect MET exon 14 skipping (METex14) and MET amplification in patients with advanced NSCLC: Biomarker analysis from VISION study*	**Xiuning Le, M.D., Ph.D.**
9:00-11:00 a.m. EDT (10:20-10:30 a.m.)	Virtual Minisymposium – Cancer Epigenetics	*1083: Heterozygous knockout of the histone modifier MLL4 promotes Ptch+/--driven medulloblastoma*	**Shilpa S. Dhar, Ph.D.**
9:00-11:00 a.m. EDT (10:20-10:30 a.m.)	Virtual Minisymposium – Targeting Endocrine Pathways in Cancer	*5678: Novel glucocorticoid receptor degrading bifunctional molecules as therapeutics in castration-resistant prostate cancer*	**Yonathan Lissanu Deribe, Ph.D.**

9:00-11:00 a.m. EDT (10:35-10:45 a.m.)	Virtual Minisymposium – New Insight from Classic Epidemiologic Factors	*3397: Whole exome sequencing case-control study implicates truncating variants in ATM as major risk factors in pancreatic cancer*	**Paul A. Scheet, Ph.D.**
12:45-2:45 p.m. EDT (12:45-1:05 p.m.)	Virtual Methods Workshop – Clinical Trial Design: Part 2: Clinical Trials Issues with Molecularly Targeted Agents	*Challenges in precision medicine clinical trials and drug development*	**Jordi Rodon Ahnert, M.D., Ph.D.**
12:45-2:45 p.m. EDT (1:45-2:05 p.m.)	Virtual Methods Workshop – Clinical Trial Design: Part 2: Clinical Trials Issues with Molecularly Targeted Agents	*Challenges with combining molecularly targeted agents*	**Timothy A. Yap, M.D., Ph.D.**
3:00-5:00 p.m. EDT (4:00-4:20 p.m.)	Virtual Educational Session – Noncoding RNA in Cancer Progression	*About Chomsky, patterns, noncoding RNAs, and cancer patients*	**George A. Calin, M.D., Ph.D.**

Tuesday, June 24

TIME	SESSION	ABSTRACT	PRESENTER
9:00-10:30 a.m. EDT (9:00-9:05 a.m.)	Virtual Minisymposium – Immune Checkpoints: Clinical Aspects	*Session Chairperson - Introduction*	**Lauren Averett Byers, M.D.**
9:00-10:45 a.m. EDT (9:20-9:30 a.m.)	Virtual Minisymposium – Emerging Mechanisms of Resistance to Targeted Therapies	*5682: Synergism of PARP inhibitor and MET inhibitor in multiple cancer types with intrinsic and acquired PARP inhibitor resistances*	**Mei-Kuang Chen**

9:00-10:45 a.m. EDT (10:35-10:45 a.m.)	Virtual Minisymposium – Emerging Mechanisms of Resistance to Targeted Therapies	*Session Co-Chairperson – Closing Remarks*	**Funda Meric-Bernstam, M.D.**
9:00-10:15 a.m. EDT (9:20-9:30 a.m.)	Virtual Minisymposium – Cancer Immunity	*3421: Identifying mechanisms of immune evasion in microsatellite instable endometrial cancers*	**Brenda Melendez, Ph.D.**
9:00-10:45 a.m. EDT (9:50-10:00 a.m.)	Virtual Minisymposium – Emerging Mechanisms of Resistance to Targeted Therapies	*5683: Single-cell RNA-seq reveals heterogeneity, clonal evolution and strategies to overcome ibrutinib-venetoclax dual resistance in mantle cell lymphoma*	**Changying Jiang, Ph.D.**
9:00-11:00 a.m. EDT	NextGen Stars Spotlight Session II – Immunology and Breast Cancer	*Session Chairperson*	**Jennifer A. Wargo, M.D.**
9:00-11:00 a.m. EDT (10:00-10:15 a.m.)	NextGen Stars Spotlight Session II – Immunology and Breast Cancer	*8: Proteome instability is an immunogenic therapeutic vulnerability in mismatch repair deficient cancer*	**Nidhi Sahni, Ph.D.**
9:00-11:00 a.m. EDT (10:35-10:45 a.m.)	Virtual Minisymposium – Bioinformatics and Artificial Intelligence for Cancer Research and Development	*3383: DrOncoRight: A natural language-oriented analytics platform for cancer omics data*	**Jun Li, Ph.D.**
9:00-11:00 a.m. EDT (10:35-10:45 a.m.)	Virtual Minisymposium – Transcriptional Gene Regulation in Cancer	*3433: Identification of a subtype specific molecular field across the mammary gland of breast cancer patients*	**Isabelle Bedrosian, M.D.**

1:45-3:45 p.m. EDT (1:45-2:05 p.m.)	Virtual Educational Session – The Microbiome as a Regulator of the Immune Tumor Microenvironment	*Session Chairperson - Implications of finding bacteria in pancreatic tumors*	**Florencia McAllister, M.D.**
4:00-6:00 p.m. EDT (4:00-4:20 p.m.)	Virtual Methods Workshop – Models and Methods to Dissect Toxicity in Cancer Treatment	*Session Chairperson - Understanding and combating mechanisms of immune-related adverse events to checkpoint blockade*	**Stephanie S. Watowich, Ph.D.**
4:00-5:30 p.m. EDT (4:30-4:50 p.m.)	Virtual Methods Workshop – Data Resources for Cancer Research	*DrOncoRight: A natural language-oriented, AI-driven analytics for cancer omic data*	**Han Liang, Ph.D.**
4:00-6:00 p.m. EDT (5:00-5:20 p.m.)	Virtual Educational Session – Immunotherapy, Immune Evasion in Myeloid Malignancies, and Therapeutic Implications	*Targeting the immune checkpoints: Taking off the brakes*	**Naval Daver, M.D.**
4:00-6:00 p.m. EDT (5:30-5:50 p.m.)	Virtual Methods Workshop – Clinical Trial Design: Part 4: Trial Design for Early Cancer Detection	*Cancer prevention/immunoprevention strategies for high-risk cancers (Lynch syndrome)*	**Eduardo Vilar-Sanchez, M.D., Ph.D.**

ON-DEMAND POSTER PRESENTATIONS		
SESSION	**ABSTRACT**	**PRESENTER**
Antibody Drug Conjugates	*2891: Targeting breast cancer stem cells with anti-EMP2 immunotoxins delivering granzyme b*	**Khalid A. Mohamedali, Ph.D.**
Autophagy and Cancer	*1237: Biological effects of a FRα-targeting antibody-drug conjugate, IMGN853 (mirvetuximab soravtansine) in high-grade serous ovarian cancer*	**Anca Chelariu-Raicu, M.D., Ph.D.**
Cancer Stem Cells	*3801: Oxidative stress induces glutamine-dependent GD2+ triple negative breast cancer stem cells*	**Appalaraju Jaggupilli, Ph.D.**
Causes and Consequences of Tumor Heterogeneity	*1496: Paired, single-cell profiling of circulating tumor cell-derived xenograft models of small cell lung cancer reveals intratumoral heterogeneity and emergence of new cell clusters following treatment relapse*	**C. Allison Stewart, Ph.D.**
Causes and Consequences of Tumor Heterogeneity	*1497: Longitudinal response and selection under neoadjuvant systemic therapy (NAST) in triple-negative breast cancer (TNBC): Profiling results from a randomized trial (ARTEMIS - NCT02276443)*	**Sahil Seth, Ph.D.**
Causes and Consequences of Tumor Heterogeneity	*1513: Analysis of spatiotemporal phenotypic heterogeneity in chemoresistant triple negative breast cancer using imaging mass cytometry*	**Amanda Rinkenbaugh, Ph.D.**
Causes and Consequences of Tumor Heterogeneity	*1516: Deep profiling of T-cell repertoire and tumor heterogeneity in chronic lymphocytic leukemia patients following allogeneic T-cell therapy*	**Celine Kerros, Ph.D.**
Causes and Consequences of Tumor Heterogeneity	*1518: A single-cell transcriptomic atlas of lung adenocarcinoma and adjacent normal-appearing tissue*	**Ansam Sinjab, Ph.D.**

Cell Death in Cancer	*2415: H2A monoubiquitination links glucose availability to epigenetic regulation of the endoplasmic reticulum stress induced cell death in cancer*	**Yilei Zhang, Ph.D.**
Cell Signaling	*122: Targeting forward and reverse EphB4/EFNB2 signaling by a peptide with dual functions*	**Chiyi Xiong, Ph.D.**
Cell Surface Antigens and Receptors as Drug Targets	*5176: A novel, completely human fusion construct containing active Granzyme B efficiently kills Folate Receptor alpha positive tumor cells*	**Ana Alvarez de Cienfuegos, Ph.D.**
Cell Surface Antigens and Receptors as Drug Targets	*5180: Nuclear receptor tyrosine kinase c-MET restrains efficacy of PARP inhibitor in pancreatic cancer cells*	**Yuan Gao**
Cell Surface Antigens and Receptors as Drug Targets	*5194: Development of a cytotoxic fusion protein targeting VEGF receptors with improved cytotoxicity, stability and pharmacokinetics*	**Khalid A. Mohamedali, Ph.D.**
Circulating Markers 2	*1979: Enhancing cell-free DNA and mutant copy recovery from plasma with novel liquid-liquid extraction*	**Filip Janku, M.D., Ph.D.**
Clinical and Preclinical Precision Medicine: Next-Generation Sequencing, Functional, and Pharmacogenomics	*827: Elucidating transcriptomic signatures in leukemia stem cells and minimal residual disease following treatment of adverse risk AMLs*	**Vakul Mohanty, Ph.D.**
Clinical and Preclinical Precision Medicine: Next-Generation Sequencing, Functional, and Pharmacogenomics	*829: Global tumor transcriptional activity reveals aggressiveness across multiple cancers*	**Shaolong Cao, Ph.D.**
Clinical Prevention, Early Detection, and Interception 1	*1121: Baseline oral microbiota profiles associated with all-cancer incidence in a cohort of non-smoking Mexican American women*	**Xiaotao Zhang, Ph.D.**
Clinical Prevention, Early Detection, and Interception 1	*1140: Declining awareness of HPV and HPV vaccination within the general US population*	**Onyema G. Chido-Amajuoyi, Ph.D.**

Combination Immunotherapies 1	*908: BRAF inhibition and nanoparticle-delivered cytokine therapy for melanoma: A novel rational combined approach*	**Gabriele Romano, Ph.D.**
Combination Immunotherapies 1	*921: TLR5 agonists enhance anti-tumor immunity and overcome resistance to immune checkpoint therapy*	**Caleb Gonzalez, Ph.D.**
Combination Immunotherapies 3	*4449: Plinabulin, a microtubule destabilizing agent, improves tumor control by enhancing dendritic cell maturation and CD8 T cell infiltration in combination with immunoradiotherapy*	**Shinya Neri, Ph.D.**
Combination Immunotherapies 3	*4454: TUSC2 immunogene therapy enhances efficacy of immunotherapy and targeted drugs in human non-small cell lung cancer (NSCLC) in humanized mouse models*	**Ismail M. Meraz, Ph.D.**
Diagnostic Markers	*738: Utility of Assessing HER2 RNA expression for precision medicine*	**Yifei Shen, Ph.D.**
DNA-reactive Agents and Other	*5210: Novel SIK2 inhibitors sensitize ovarian and breast cancer to PARP inhibitors*	**Zhen Lu, M.D.**
Drug Combinations	*548: Birinapant enhances gemcitabine's anti-tumor efficacy in triple-negative breast cancer by inducing intrinsic pathway-dependent apoptosis*	**Xuemei Xie, Ph.D.**
Drug Combinations	*550: Determining efficacy of drug combinations identified by unbiased high throughput screening for RAS-mutated colorectal cancer*	**Rajat Bhattacharya, Ph.D.**
Drug Combinations	*555: Mitochondrial fusion exerts KRAS-dependent therapeutic synergy with gemcitabine/nab-paclitaxel in preclinical models of pancreatic cancer*	**Nicholas D. Nguyen**
Drug Combinations	*557: Novel targeted combination therapies active in KRAS mutant non-small cell lung cancer (NSCLC) identified using patient-derived xenografts (PDX)*	**Bingliang Fang, M.D., Ph.D.**

Drug Combinations	*569: Rational combination approaches with CRM-1 inhibitor in ovarian cancer*	**Katelyn F. Handley, M.D.**
Drug Targets in the Microenvironment	*6038: Combined targeting of E-selectin/CXCR4 and FLT3 by GMI-1359 and sorafenib effectively reduces leukemia cell burden and protects normal hematopoiesis in a patient-derived AML xenograft model*	**Weiguo Zhang, M.D., Ph.D.**
Epigenetic Changes as Molecular Markers of Cancer 1	*1248: DNA methylation biomarkers for MPNST detection in patients with neurofibromatosis type 1*	**Katarzyna J. Tomczak, Ph.D.**
Epigenetic Regulation of Metastasis	*3844: EZH2 engages TGF-β signaling to promote breast cancer bone metastasis*	**Yu-Wen Huan**
Gene and Vector-Based Therapy	*4053: Mucin 5ac as a potential therapeutic target for KRAS-driven lung adenocarcinoma*	**Walter V. Velasco Torrez, M.D.**
Gene Expression in the Microenvironment 2 / Tumor Dormancy	*2631: Deep learning-based analysis of tissue segmentation in histopathology images of colorectal cancer*	**Sunyoung S. Lee, M.D., Ph.D.**
Gene Regulation and Transcription Factors 1	*1303: PRTN3, RGCC and SLCO4C1 are critical SOX9-regulated genes that control TNBC growth*	**Yanxia Ma, M.D., Ph.D.**
Genetic and Epigenetic Regulation of Tumor Suppression	*4711: Novel mechanism involved in the regulation ofoncogenic Axl receptor tyrosine kinase in cancer*	**Hua Wang, M.D., Ph.D.**
Genomic Profiling of Tumors 3	*2501: Delineating mutational lineages with single cell DNA sequencing using multi-patient specific panels*	**Jake Leighton**
Genomic Profiling of Tumors 3	*2510: High-depth whole genome sequencing of clinically-annotated high-grade serous ovarian cancers*	**Sanghoon Lee, Ph.D.**

Genomic Profiling of Tumors and Microarrays	*3612: Integrated genomic analysis of gastroesophageal adenocarcinoma reveals molecular determinants of patient outcomes*	**Dapeng Hao, Ph.D.**
Identification of Molecular Targets 2	*2941: Functional proteomic aberrations post-chemotherapy with paclitaxel and carboplatin in patients with advanced ovarian cancer*	**Sanghoon Lee, Ph.D.**
Imaging the Tumor Immune Landscape and Immune Cell Interactions	*379: Myeloperoxidase-produced HOCl is a paracrine effector linking myeloid cells to NF-κB signaling in melanoma, mediating anti-tumor responses during early melanoma progression*	**Tracy W. Liu, Ph.D.**
Immune Cells in the Tumor Microenvironment 2	*2658: Immunological and mutational landscape of gallbladder adenocarcinoma*	**Fernando Cintra Lopes Carapeto, D.V.M.**
Immune Cells in the Tumor Microenvironment 2	*2663: Identification of differential immune landscapes in high-grade serous ovarian tumors of high-risk patients by imaging mass cytometry*	**Han Cun, M.D.**
Immune Cells in the Tumor Microenvironment 2	*2679: Immuno-oncology panel optimization for imaging mass cytometry and digital image analysis of tumor tissues*	**Pedro Rocha, M.D.**
Immune Cells in the Tumor Microenvironment 3	*3857: Characterization of immune cell biomarkers in undifferentiated pleomorphic sarcoma*	**Carmelia M. N. Barreto, M.D.**
Immune Checkpoints 2	*2232: A novel immune checkpoint regulator in the ovarian cancer microenvironment*	**Sammy Ferri Borgogno, Ph.D.**
Immune Checkpoints 3	*3267: Identification of a novel biomarker response in a prospective clinical trial of immune checkpoint blockade in recurrent ovarian carcinoma*	**Han Cun, M.D.**
Immunity and the Microenvironment	*399: Tertiary lymphoid structures features associate with outcome in non-small cell lung carcinoma*	**Rossana Natalia Lazcano Segura, M.D.**

Immunogenomics	*4493: Enhancer reprogramming contributes to anti-PD1 resistance in melanoma*	**Mayinuer Maitituoheti, Ph.D.**
Implementation Science	*5747: A single center's ten-year experience in sustaining a cancer survivorship program*	**Guadalupe Palos, Dr.PH.**
Knowledge, Networks, Graphs, and Models for Discovery	*4393: Identifying novel therapeutic targets in cancers by elucidating the regulatory mechanics of genes insensitive to gene dosage changes*	**Vakul Mohanty, Ph.D.**
Knowledge, Networks, Graphs, and Models for Discovery	*4396: A bioinformatics approach for cancer immunotherapeutic target identification by evaluating surfaceome gene and protein expression (CITIESGAPE) in tumor and pan-normal tissues*	**Xiangjun Tian, Ph.D.**
Late-Breaking Research: Tumor Biology 2	*LB-217 : Preclinical evaluation of trastuzumab deruxtecan (T-DXd - DS-8201a), a HER2 antibody-drug conjugate, in pediatric solid tumors by the Pediatric Preclinical Testing Consortium (PPTC)*	**Pooja Hingorani, M.D.**
Machine Learning	*2107: Seeing glycolysis on PDAC: Applying deep learning convolutional neural network model*	**Chang-Jiun Wu, Ph.D.**
Mechanisms of Resistance and Sensitivity to Targeted Therapy in Hematopoietic Tumors	*652: Exploiting PRMT5, a metabolic and epigenetic regulator, as a novel therapeutic target in mantle cell lymphoma*	**Yixin Yao, Ph.D.**
Mechanisms of Resistance and Sensitivity to Targeting HER2 and Downstream RAS/PI3K/MEK Pathways	*1897: Mechanism of MEK inhibitor resistance in triple negative breast cancer*	**Moises Tacam**
Mechanisms of Sensitivity and Resistance to Targeted Therapy 1	*3011: Phase I study of TT-00420, a multiple kinase inhibitor, in patients with triple negative breast cancers and other advanced solid tumors*	**Sarina A. Piha-Paul, M.D.**
Mechanisms of Sensitivity and Resistance to Targeted Therapy 3	*6331: Cloaking VEGF in small extracellular vesicles as a cause of adaptive resistance to anti-VEGF therapy*	**Shaolin Ma, M.D., Ph.D.**

Mechanisms of Sensitivity and Resistance to Targeting DNA Damage Repair	*4074: Reversing acquired PARPi resistance of TNBC through combined inhibition of cMet and EGFR*	**Yu Yi Chu, Ph.D.**
Mechanisms of Sensitivity and Resistance to Targeting DNA Damage Repair	*4083: Crizotinib improves the therapeutic efficacy of olaparib in ovarian cancer*	**Janice M. Santiago-O'Farrill, Ph.D.**
Mechanisms of Tumor Suppressor Genes	*5985: MiR-329 mimic based nano-therapy inhibits growth and progression of triple negative breast cancer*	**Goknur Kara, Ph.D.**
Mechanisms Underlying Immuno-oncology Therapies and Response and Resistance to Therapy in Pediatric Oncology	*5011: Exercise prevents late Doxorubicin-induced vascular damage, decreases late-onset heart failure and fibrosis, and improved recovery from MI*	**Fei Wang, M.D., Ph.D.**
Mechanisms Underlying Immuno-oncology Therapies and Response and Resistance to Therapy in Pediatric Oncology	*5012: Exercise as a novel method of tumor vascular remodeling*	**Keri Schadler, Ph.D.**
Metabolic Pathways in Cancer	*232: Comprehensive metabolic profiling and vulnerabilities to metabolic inhibitors among small cell lung cancer subtypes*	**Kasey R. Cargill, Ph.D.**
Metabolic Pathways in Cancer	*251: Microenvironment-modulated glutamine dependence in AML and therapeutic targeting with glutaminase inhibitor CB-839*	**Tianyu Cai, Ph.D.**
Metastasis Therapies	*5018: Hippo co-activator YAP 1 is essential for peritoneal metastases in gastric adenocarcinoma and targeting YAP 1 is a novel therapeutic strategy*	**Shumei Song, M.D., Ph.D.**
Metastasis Therapies	*5027: The mu-opioid receptor antagonist methylnaltrexone can decrease tumorigenesis in head and neck squamous cell carcinoma*	**Aysegul Gorur, Ph.D.**
Metastasis Therapies	*5043: A vimentin binding small molecule (FiVe1) is a novel candidate to target CSC-rich TNBC*	**Nick A. Kuburich, Ph.D.**

Microbiome, Inflammation, and Cancer	*3349: Evolution of the gut microbiome during the pathogenesis of smoking-associated Kras-mutant lung cancer*	**Warapen Treekitkarnmongkol, Ph.D.**
Mitochondrial Metabolism	*4791: Metabolic switch from glycolysis to oxidative phosphorylation (ox-phos) provides survival advantage to anti-androgen-treated prostate cancer cells and make them vulnerable to mitochondrial metabolism inhibitors IACS-010759 and CB-839*	**Hirak S. Basu, Ph.D.**
Model Organisms for Cancer Research	*6136: Generation and characterization of colorectal cancer cell lines from the Buffalo rat*	**Nina M. Muñoz, Ph.D.**
Modulation of DNA Repair, New Nonclinical Models for Targets, and Other Targets	*4143: Identification of molecular targets for conservative management of early stage, low-grade endometrial cancer through compartment-specific transcriptome profiling*	**Qian Zhang, Ph.D.**
Molecular Markers, Targets, and Microbiome	*1150: Targeting PI3K inhibits ER-mammary tumor initiation and early dissemination*	**Yuan Zhang, Ph.D.**
Mouse Models of Human Cancer in Imaging and Therapeutics	*2751: Potential of 6-mercaptopurine and 5-azacitidine in halting progression of poor prognosis residual disease in triple negative breast cancer*	**Balraj Singh, Ph.D.**
Natural Products as Starting Points for Cancer Drug Discovery	*6549: Preventive effect of compound Kushen injection in radiation induced lung pneumonitis*	**Ting Xu, Ph.D.**
New and Improved Models for the Study of Pediatric Malignancies	*6150: The role of oxidative phosphorylation in a novel iPSC <->derived model of osteosarcomagenesis*	**Brittany Ellis Jewell**
Non-coding RNAs in Cancer 4	*3704: MicroRNA-3977 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting FoxM1*	**Selda Karamil, Ph.D.**
Non-coding RNAs in Cancer 5	*4815: Differential expression profiling of long noncoding RNA establishes UCA1 as a hallmark of renal medullary carcinoma.*	**Pavlos Msaouel, M.D., Ph.D.**

Non-ionizing Radiation and Radiation Immune Responses	*473: Preclinical model of radiation induced lymphopenia to identify abrogation strategies to enhance cancer therapy*	**Amrish Sharma, Ph.D.**
Novel Antitumor Agents 2	*5321: Novel imipridone ONC206 inhibits cell proliferation and induces apoptosis in uterine serous cancer through altering MAPK/AKT signaling network and metabolic reprogramming*	**Chi Lam Au Yeung, Ph.D.**
Novel Antitumor Agents 2	*5335: CA102N suppresses the growth of mouse colon cancer by inhibition of PI3K pathway and immune modulation*	**Peiying Yang, Ph.D.**
Novel Therapeutic Approaches	*6417: LY3410738, a novel inhibitor of mutant IDH1 is more effective than Ivosidenib and potentiates antileukemic activity of standard chemotherapy in preclinical models of acute myeloid leukemia (AML)*	**Vivian Salama**
Nuclear Oncogenes and Tumor Suppressor Genes	*295: Protein phosphatase, Mg2+/Mn2+ dependent 1G promotes proliferation via modulating phosphorylation of retinoblastoma protein and associates with poor outcome in hepatocellular carcinoma*	**Wen Hu**
Nuclear Oncogenes and Tumor Suppressor Genes	*298: FOXC1-mediated LINC00301 facilitates tumor progression and immune-suppressing microenvironment in NSCLC by regulating the HIF1α pathway*	**Chengcao Sun, Ph.D.**
Patient-derived Xenograft Models 1	*1662: In vivo drug response evaluation in anaplastic thyroid cancer patient-derived tumor xenografts following high-throughput screening*	**Anastasios Maniakas, M.D.**
Pediatric Cancer: Preclinical and Clinical Investigations	*5405: Integrative surfaceome profiling identifies MMP14, MRC2 and CD276 as candidate immunotherapeutic target in osteosarcomas*	**Yifei Wang, M.D.**
Pediatric Cancer: Preclinical and Clinical Investigations	*5415: Profiling cancer testis antigens in osteosarcomas*	**Zhongting Zhang**
Pediatric Cancer: Preclinical and Clinical Investigations	*5422: Dissecting the mechanism of exercise-mediated protection of Dox-induced cardiotoxicity*	**Rong-Hua Tao, Ph.D.**

Phase I Clinical Trials	*CT163: Temsirolimus in combinaton with metformin in patients with advanced or refractory endometrial cancers*	**Aung Naing, M.D.**
Phase II Clinical Trials	*CT204: High cytotoxic T-cell or polymorphonuclear cell infiltrates in the tumor microenvironment correlate with responses to BL8040 plus pembrolizumab combination therapy in metastatic pancreatic tumors: Scientific correlates of a phase II clinical trial*	**Edwin R. Parra, Ph.D.**
PI3K/AKT/mTOR Inhibitors	*676A : Overcoming PARP inhibitor resistance with molecularly guided rational combinations in triple-negative breast cancer patient-derived xenograft models*	**Christian X. Cruz Pico, M.D.**
Preclinical Prevention Studies	*1: Sulindac plus phospholipid is effective for polyp reduction and safer than sulindac alone*	**Jennifer Sarah Davis, Ph.D.**
Preclinical Prevention Studies	*17: Ex-vivo assessment of the effect of Simvastatin in intestinal epithelium of Lynch Syndrome patients*	**Prashant Bommi, Ph.D.**
Preclinical Prevention Studies	*20: Fluvastatin inhibits the development of breast cancer in SV40C3Tag mouse model of triple negative breast cancer*	**Anjana Bhardwaj, Ph.D.**
Predictive Biomarkers for Precision Medicine	*787: Comparable clinical benefits between low and high variant allelic frequency in NSCLC patients treated with targeted therapies based on molecular alterations from ctDNA NGS*	**Hai T. Tran, Pharm.D.**
Predictive Biomarkers for Treatment Efficacy 3	*4286: TGF-β signature is a therapeutic biomarker for combination immunotherapy for hepatocellular carcinoma*	**Jian Chen, M.D., Ph.D.**
Proteomics and Biomarker Discovery	*5139: An atlas of perturbed functional proteomics profiles of cancer cell lines*	**Jun Li, Ph.D.**
Screening, Lead Identification, and Optimization	*515: Synthesis of phosphoramidate-based pro-drugs of the enzyme enolase for the treatment of ENO1-deleted glioblastoma*	**Victoria C. Yan**

Signaling Networks and the PI3K/AKT/mTOR Pathway in Cancer	*1439: NUDT5 is a critical regulator of triple-negative breast cancer growth*	**Jing Qian**
Signaling Pathways to Metabolism 2	*2557: 15-lipoxygenase-1 suppresses linoleic acid promotion of colorectal tumorigenesis through oxidative metabolism of PI3P_linoleic acid to inhibit membranous LRP5 recycling and WNT/β-catenin signaling activation*	**Yi Liu, Ph.D.**
Targeting Tumor Microenvironment, Protein Kinases/Phosphatases, and Other Strategies	*3054: Targeting TGF-β signaling for obesity/insulin resistance-associated hepatocellular carcinoma*	**Jian Chen, M.D., Ph.D.**
Therapeutic Antibodies 5 / Vaccines	*6527: Targeting glycosylated PD-1 induces potent anti-tumor immunity*	**Yuhan Wang**
Topoisomerases, Tubulin, and Other Small Molecule Therapeutic Agents	*3074: Targeting sanctuary sites of cancer: Novel approaches to treatment of lung localized tumors*	**Waldemar Priebe, Ph.D.**
Topoisomerases, Tubulin, and Other Small Molecule Therapeutic Agents	*3075: Anti-leukemic activity of BCL-2/BCL-XL dual inhibitor - AZD0466 in T-acute lymphoblastic leukemia preclinical models*	**Sankaranarayanan Kannan, Ph.D.**
Translational Research with Immune Therapies	*2049: Cytokines associated with prolonged Cytopenia after axicabtagene ciloleucel in patients with refractory large B-cell lymphoma*	**Paolo Strati, M.D.**
Tumor Heterogeneity and Microenvironment: Next-Generation Sequencing, Single Cell, and Imaging	*4416: Modeling cancer-immune co-evolution from single-cell RNA-seq data*	**Jinzhuang Dou, Ph.D.**
Tumor Heterogeneity and Microenvironment: Next-Generation Sequencing, Single Cell, and Imaging	*4424: Medatree enabling single cell copy number lineage tracing and functional discovery*	**Fang Wang, Ph.D.**
Tumor Induced Immune Suppression	*1027: Inhibition of c-MET upregulates PD-L1 related immune escape in lung adenocarcinoma*	**Xian Sun, M.D.**

Tumor Microenvironment 1	*3947: Mass-spectrometry analysis of metastatic matrisome from MC38 experimental liver metastasis*	**Arseniy E. Yuzhalin, Ph.D.**
Tumor Microenvironment 2	*5066: Investigating the role of IL-6 to modulate the immunosuppressive tumor microenvironment of EGFR mutant NSCLC*	**Sonia A. Patel**
Tumor Microenvironment 2	*5067: Suppression of tumorigenicity and metastasis of triple-negative breast cancer (TNBC) by c-Jun N-Terminal Kinase (JNK) inhibitor via reversing immunosuppressive tumor microenvironment (TME)*	**Takashi Semba, M.D., Ph.D.**
Tumor Microenvironment 3	*6202: Effect of sympathetic nervous system mediators on the tumor microenvironment via small extracellular vesicles in ovarian cancer*	**Sujanitha Umamaheswaran**
Tumor Type-focused Translational Research Specific	*5443: Modulating plasticity in aggressive variant prostate cancers*	**Rama Soundararajan, Ph.D.**
Tumor/Stromal Interactions 1	*3985: GDF15 expression level impacts the canonical pathways of the tumor microenvironment and ovarian tumors with wild-type p53 in response to chemotherapy*	**Kwong-Kwok Wong, Ph.D.**
Tumor-immune System Interactions 2	*2822: Single-cell evaluation to identify tumor-stroma niches driving the transition from in situ to invasive breast cancer*	**Vidya C. Sinha, Ph.D.**